Citations

Clear

3942 citation(s) found for "To, Van".

The new Roche Elecsys TSH assay conforms with current IFCC C-STFT standards
Kratzsch, Jüergen, Baumann, N, Ceriotti, Ferruccio , Lu, Zhong X. , Herwaarden, Antonius E. van , Lehmann, H. , Kasapic, Dusanka , Giovanella, Luca , Baumann, Nikola A, Giovanella, Luca , Schott, Matthias , Vieira, José Gilberto H. , Lehmann, Holger

Mayo Clinic

Clinical Chemistry and Laboratory Medicine (CCLM) | July 12, 2021 | Volume: 59 | Issue: 12 | Pages: e445-e448

10.1515/cclm-2021-0352 | PMID 34252995 Get It

Activation Pattern During His-Bundle Pacing
Yasin, Omar , Bush, Jaime, Vaidya, Vaibhav R. , Tri, Jason , Zyl, Martin van , Xiao, Peilin , Scheuermann, Cory, Asirvatham, Samuel J. , Cha, Yong‐Mei , Asirvatham, Samuel J , Xiao, Peilin , Han, Jie

Mayo Clinic

No container title available | July 11, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.162602806.64990926/v1 Get It

Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit
Semb, Anne Grete , Rollefstad, Silvia , Ikdahl, Eirik , Wibetoe, Grunde , Sexton, Joseph, Crowson, Cindy S., Riel, Piet L. C. M. van , González‐Gay, Miguel Á. , Sfikakis, Petros P. , Tektonidou, Maria G. , Lazarini, Argyro , Vassilopoulos, Dimitrios , Kuriya, Bindee , Durez, Patrick , Pascual‐Ramos, Virginia , Galarza-Delgado, D. Á. , Misra, Durga Prasanna , Borg, Andrew , Mu, Rong , Мirrakhimov, Erkin М , Gheta, Diane, Douglas, Karen, Agarwal, Vikas , Myasoedova, S. Е. , Krougly, Lev B. , Tuchyňová, Alena, Tomčík, Michal , Laštůvka, Jiří, Hořák, Pavel , Medková, Helena, Kerola, Anne M , Crowson, Cindy, Karpouzas, George Athanasios , Gonzalez-Gay, Miguel A , Tektonidou, Maria G , Durez, Patrick , Pascual-Ramos, Virginia , Galarza-Delgado, Dionicio Angel , Misra, Durga Prasanna , Agarwal, Vikas , Valentinovna Popkova, Tatiana , Semb, Anne Grete , Kitas, George D. , Graham, Ian , Rantapää‐Dahlqvist, Solbritt , Karpouzas, George , Myasoedova, Elena , Hitchon, Carol , Stoenoiu, Maria Simona , Faggiano, Pompilio Massimo , Vrablı́k, Michal

Mayo Clinic

RMD Open | July 8, 2021 | Volume: 7 | Issue: 2 | Pages: e001724

10.1136/rmdopen-2021-001724 | PMID 34244381 Get It

Aim The objective was to examine the prevalence of atherosclerotic cardiovascular disease (ASCVD) and its risk factors among patients with RA with diabetes mellitus (RA-DM) and patients with RA without diabetes mellitus (RAwoDM), and to evaluate lipid and blood pressure (BP) goal attainment in RA-DM and RAwoDM in primary and secondary prevention. Methods The cohort was derived from the Survey of Cardiovascular Disease Risk Factors in Patients with Rheumatoid Arthritis from 53 centres/19 countries/3 continents during 2014–2019. We evaluated the prevalence of cardiovascular disease (CVD) among RA-DM and RAwoDM. The study population was divided into those with and without ASCVD, and within these groups we compared risk factors and CVD preventive treatment between RA-DM and RAwoDM. Results The study population comprised of 10 543 patients with RA, of whom 1381 (13%) had DM. ASCVD was present in 26.7% in RA-DM compared with 11.6% RAwoDM (p<0.001). The proportion of patients with a diagnosis of hypertension, hyperlipidaemia and use of lipid-lowering or antihypertensive agents was higher among RA-DM than RAwoDM (p<0.001 for all). The majority of patients with ASCVD did not reach the lipid goal of low-density lipoprotein cholesterol <1.8 mmol/L. The lipid goal attainment was statistically and clinically significantly higher in RA-DM compared with RAwoDM both for patients with and without ASCVD. The systolic BP target of <140 mm Hg was reached by the majority of patients, and there were no statistically nor clinically significant differences in attainment of BP targets between RA-DM and RAwoDM. Conclusion CVD preventive medication use and prevalence of ASCVD were higher in RA-DM than in RAwoDM, and lipid goals were also more frequently obtained in RA-DM. Lessons may be learnt from CVD prevention programmes in DM to clinically benefit patients with RA .
Second Primary Tumors in Patients Presenting With Unilateral HPV‐Associated Tonsillar Squamous Cell Carcinoma
McMillan, Ryan A. , Abel, Kathryn M. Van , Routman, David M. , Wittich, Michelle A. Neben, Kasperbauer, Jan L. , Price, Katharine R., Moore, Eric J. , Van Abel, Kathryn M , Yin, Linda X , Routman, David M , Neben Wittich, Michelle A, Kasperbauer, Jan , Moore, Eric J , McMillan, Ryan A , Yin, Linda X. , Daniel, J. , Price, Daniel L. , Chintakuntlawar, Ashish V.

Mayo Clinic

The Laryngoscope | July 8, 2021 | Volume: 132 | Issue: 2 | Pages: 332-338

10.1002/lary.29741 | PMID 34236086 Get It

ObjectiveTo describe and compare rates of metachronous and synchronous second primaries of the contralateral tonsil in patients with primary HPV(+) tonsillar squamous cell carcinoma (SCC).Study DesignRetrospective cohort study.Materials and MethodsThis is a single tertiary care center retrospective case series, from 2006 to 2019, of HPV(+) tonsillar SCC patients who underwent primary surgical resection with unilateral wide‐field tonsillectomy or bilateral tonsillectomy for diagnostic or therapeutic purposes. A metachronous second primary is one diagnosed >6 months after completion of surgical treatment. A synchronous second primary is one diagnosed during bilateral tonsillectomy for unilateral HPV(+) tonsillar SCC. Rates of second primary and patient characteristics were compared using chi‐square tests.ResultsAbout 303 patients underwent unilateral surgical resection +/− adjuvant therapy for HPV(+) tonsillar SCC. One (0.3%) developed a metachronous second primary in the contralateral tonsil 11.9 years following treatment. Fifty‐seven patients with HPV(+) tonsillar SCC underwent bilateral tonsillectomy, and 37/57 (65%) had no clinical signs for contralateral disease. Of these, only 1/37 (2.7%) was incidentally found to have a synchronous second primary. Twenty patients underwent bilateral tonsillectomy due to clinical concern for contralateral disease. Of these, 3/20 (15%) were found to have a synchronous HPV(+) SCC in the contralateral tonsil.ConclusionsThe prevalence of metachronous second primary after appropriate treatment of HPV(+) tonsillar SCC is very low (0.3%) and so is the chance of incidentally discovering a synchronous second primary during bilateral tonsillectomy (2.7%). We do not recommend bilateral tonsillectomy as a part of the routine algorithm in the surgical management of these patients.Level of Evidence3 Laryngoscope, 132:332–338, 2022
The safety of COVID‐19 convalescent plasma donation: A multi‐institutional donor hemovigilance study
Cho, Joseph H. , Rajbhandary, Srijana , Buren, Nancy L. Van , Al‐Ghafry, Maha , Fridey, Joy, Dy, Beth A., Ziman, Alyssa , Schreiber, George B. , Gammon, Richard R. , Reik, Rita A., Stubbs, James R. , Buskirk, Camille M. van , Kamel, Hany , Townsend, Mary , Zeller, Michelle P. , Gottschall, Jerome L. , van Buren, Nancy L , Fung, Mark K , Ziman, Alyssa , Schreiber, George B , Gammon, Richard R , Stubbs, James R , van Buskirk, Camille M, Townsend, Mary J

Mayo Clinic

Transfusion | July 6, 2021 | Volume: 61 | Issue: 9 | Pages: 2668-2676

10.1111/trf.16572 | PMID 34227689 Get It

AbstractBackgroundAlthough the safety and therapeutic efficacy of COVID‐19 convalescent plasma (CCP) has been extensively evaluated, the safety of CCP donation has not been explored in a multi‐institutional context.Study design and methodsNine blood collection organizations (BCOs) participated in a multi‐institutional donor hemovigilance effort to assess the safety of CCP donation. Donor adverse events (DAEs) were defined according to the Standard for Surveillance of Complications Related to Blood Donation, and severity was assessed using the severity grading tool. Multivariate analysis was performed to determine attributes associated with DAE severity.ResultsThe overall DAE rate was 37.7 per 1000 donations. Repeat apheresis and apheresis‐naïve donors experienced adverse event rates of 19.9 and 49.8 per 1000 donations, respectively. Female donors contributed 51.9% of CCP donations with a DAE rate of 49.4 per 1000 donations. The DAE rate for male donors was 27.4 per 1000 donations. Vasovagal reactions accounted for over half of all reported DAEs (51.1%). After adjustment, volume of CCP donated was associated with vasovagal reaction severity (odds ratio [OR] 6.5, 95% confidence interval [CI] 2.5–17.1). Donor age and donation history were also associated with DAE severity. Considerable differences in DAE types and rates were observed across the participating BCOs despite the use of standardized hemovigilance definitions.ConclusionThe safety of CCP donation appears comparable to that of conventional apheresis plasma donation with similar associated risk factors for DAE types and severity.
Copy Number Variation in Parkinson's Disease: An Update from Sub‐Saharan Africa
Müller-Nedebock, Amica Corda , Fawale, Bimbo , Westhuizen, Francois H. van der , Ross, Owen A. , Bardien, Soraya , Müller-Nedebock, Amica C , Ross, Owen A , Bardien, Soraya , Komolafe, Morenikeji Adeyoyin , Carr, Jonathan

Mayo Clinic

Movement Disorders | July 6, 2021 | Volume: 36 | Issue: 10 | Pages: 2442-2444

10.1002/mds.28710 | PMID 34228376 Get It

Chemoradiation and Local Excision Versus Total Mesorectal Excision for T2N0 Rectal Cancer
Lynn, Patricio B. , Valk, Maxime J.M. van der, Claassen, Y.H.M. , Shi, Qian , Widmar, Maria , Bastiaannet, E, Velde, Cornelis J.�H. van de , García‐Aguilar, Julio , Shi, Qian

Mayo Clinic

Annals of Surgery | July 6, 2021 | Volume: 277 | Issue: 1 | Pages: e96-e102

10.1097/sla.0000000000005052 | PMID 34225302 Get It

Objective: Compare oncological long-term and short-term outcomes between patients with distal cT2NO rectal cancer treated with chemoradio-therapy and local excision (CRT + LE) and patients treated with total mesorectal excision (TME). Summary Background Data: Previous studies showed that CRT + LE is equivalent to TME in local tumor control and survival for T2N0 rectal cancer. Methods: Seventy-nine patients with cT2N0 rectal adenocarcinoma treated with CRT + LE in the ACOSOG Z6041 trial were compared to a cohort of 79 patients with pT2N0 tumors treated with upfront TME in the Dutch TME trial. Survival, short-term outcomes, and health-related quality of life (HRQOL) were compared between groups. Results: Three patients (4%) in the CRT + LE group required abdominoperineal resection, compared with 31 (40%) in the TME group. Forty TME patients (51%) required a permanent stoma. CRT-related toxicity occurred in 43% of the CRT + LE patients; however, TME patients had a higher rate of complications requiring reoperation (1 vs 9%; P = 0.03). Five-year disease-free survival {88.2% [confidence interval (CI), 77.7%–93.9%] vs 88.3% [CI, 78.7%–93.7%]; P = 0.88} and overall survival [90.3% (CI, 80.8%–95.3%) vs 88.4% (CI, 78.9%–93.8%); P = 0.82] were similar in the 2 groups. Compared to baseline, overall HRQOL decreased in the CRT + LE group and improved in the TME group. In both groups, patients with sphincter preservation had worse HRQOL scores 1 year after surgery. Conclusions: In patients who underwent CRT + LE, oncological outcomes were similar to those of patients who underwent TME, with fewer complications requiring reoperation but significant CRT toxicity. Although overall HRQOL decreased in the CRT + LE group and improved in TME patients, when considering anorectal function, results were worse in both groups.
An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis: results from 19 countries
Rollefstad, Silvia , Ikdahl, Eirik , Wibetoe, Grunde , Sexton, Joe , Crowson, Cynthia S. , Riel, Piet L. C. M. van , Graham, Ian , González‐Gay, Miguel Á. , Sfikakis, Petros P. , Tektonidou, Maria G. , Lazarini, Argyro , Vassilopoulos, Dimitrios , Kuriya, Bindee , Pascual‐Ramos, Virginia , Galarza-Delgado, D. Á. , Misra, Durga Prasanna , Borg, Andrew , Mu, Rong , Мirrakhimov, Erkin М , Gheta, Diane, Myasoedova, S. Е. , Krougly, Lev B. , Tuchyňová, Alena, Tomčík, Michal , Laštůvka, Jiří, Hořák, Pavel , Medková, Helena, Graham, Ian , Tektonidou, Maria G , Gonzalez-Gay, Miguel A , Misra, Durga Prasanna , Kitas, George D. , Rantapää‐Dahlqvist, Solbritt , Karpouzas, George , Myasoedova, Elena , Hitchon, Carol , Stoenoiu, Maria Simona , Durez, Patrick , Faggiano, Pompilio Massimo , Valentinovna Popkova, Tatiana , Vrablı́k, Michal , Semb, Anne Grete

Mayo Clinic

European Heart Journal - Cardiovascular Pharmacotherapy | July 5, 2021 | Volume: 8 | Issue: 6 | Pages: 539-548

10.1093/ehjcvp/pvab052 | PMID 34232315 Get It

Abstract Aims To assess differences in estimated cardiovascular disease (CVD) risk among rheumatoid arthritis (RA) patients from different world regions and to evaluate the management and goal attainment of lipids and blood pressure (BP). Methods and results The survey of CVD risk factors in patients with RA was conducted in 14 503 patients from 19 countries during 2014–19. The treatment goal for BP was &lt;140/90 mmHg. CVD risk prediction and lipid goals were according to the 2016 European guidelines. Overall, 21% had a very high estimated risk of CVD, ranging from 5% in Mexico, 15% in Asia, 19% in Northern Europe, to 31% in Central and Eastern Europe and 30% in North America. Of the 52% with indication for lipid-lowering treatment (LLT), 44% were using LLT. The lipid goal attainment was 45% and 18% in the high and very high risk groups, respectively. Use of statins in monotherapy was 24%, while 1% used statins in combination with other LLT. Sixty-two per cent had hypertension and approximately half of these patients were at BP goal. The majority of the patients used antihypertensive treatment in monotherapy (24%), while 10% and 5% as a two- or three-drug combination. Conclusion We revealed considerable geographical differences in estimated CVD risk and preventive treatment. Low goal attainment for LLT was observed, and only half the patients obtained BP goal. Despite a high focus on the increased CVD risk in RA patients over the last decade, there is still substantial potential for improvement in CVD preventive measures.
Abstract 298: Fibrate use in patients with type 2 diabetes
Houten, Holly K. Van , Shah, Nilay D. , McCoy, Rozalina G.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | July 3, 2021 | Volume: 6 | Issue: suppl_1 | Pages: No page available

10.1161/circoutcomes.6.suppl_1.a298 Get It

Diabetes mellitus is considered to be a coronary heart disease (CHD) equivalent, with heart disease and stroke accounting for the majority of diabetes-related deaths. As a result, patients with diabetes require aggressive treatment of CHD risk factors, including dyslipidemia. In addition to targeted reduction of LDL cholesterol, current guidelines recommend addition of a fibrate (gemfibrozil, fenofibrate, or clofibrate) in patients with established CHD and atherogenic dyslipidemia: triglycerides (TG) 200-499 mg/dL and HDL cholesterol (HDL-C) ≤40 mg/dL. Fibrates have also been recommended for patients with TG ≥500 mg/dL to reduce risk of acute pancreatitis. Yet, data supporting the use of fibrates in these settings remains variable and inconclusive. We therefore sought to provide an in-depth analysis of patterns of fibrate use among patients with type 2 diabetes between 2001 and 2010. Using Ingenix administrative claims, we identified 71,161 patients age ≥18 years old with an established diagnosis of type 2 diabetes (ICD-9 250.XX) and ≥3 years of continuous enrollment who were newly initiated on a fibrate between 2001 and 2010. Lab results were available for a subset of 18,863 (26.5%) patients, who were included in final analysis. During each 2-year period, between 77.6% - 84.1% of patients had a lipid test performed within the preceding 12 months (p=0.59 for change in testing over time). The prevalence of atherogenic dyslipidemia increased over time, from 20.8% (2001-2002) to 41.2% (2009-2010); 4.84% rise per 2-year period (p=0.002). The prevalence of severe atherogenic dyslipidemia (HDL-C ≤40 mg/dL and TG ≥500 mg/dL), also increased over time, from 9.3% in 2001-2002 to 13.6% in 2009-2010; 1.17% rise per 2-year period (p=0.002). In contrast, percent of patients with TG ≥500 mg/dL decreased over time, from 20.5% in 2001-2002 to 16.7% in 2009-2010; 1.19% decline per 2-year period (p=0.03). Initiation of new fibrate therapy in treatment naïve patients with diabetes remained constant; 2.0% in 2001-2002 and 1.6% in 2009-2010 (p=0.93). Subgroup analysis of patients with atherogenic dyslipidemia also showed no significant change in fibrate initiation over time; 11.4% in 2001-2002 and 15.7% in 2009-2010 (p=0.3). Similarly, while there was a trend toward increased initiation of fibrates among patients with TG ≥500 mg/dL, this trend was not statistically significant (27.4% in 2001-2002 and 41.6% in 2009-2010; 3.34% change per 2-year period (p=0.09)). In conclusion, the prevalence of atherogenic dyslipidemia among patients with type 2 diabetes has increased significantly over the past decade. However, fibrate use in all patients with type 2 diabetes, including those specifically with atherogenic dyslipidemia, has remained constant throughout the observation period, despite lack of conclusive evidence supporting its use.
Abstract 12776: Long Term Mortality With Right Ventricular Apical Versus Septal Pacing
Witt, Chance M. , Lenz, Charles J., Shih, Henry, Ebrille, Elisa , Rosenbaum, Andrew , Aung, Htin , Zyl, Martin van , Manocha, Kevin K. , Deshmukh, Abhishek , Hodge, David O. , Aung, Htin, Asirvatham, Samuel J. , McLeod, Christopher J.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.12776 Get It

Introduction: Right ventricular apical (RVA) pacing appears to have detrimental effects on cardiac function and long term outcomes. Right ventricular non-apical (RVNA) pacing, especially in the septal position, has been postulated as an alternative that may lead to less morbidity and mortality. Prior studies have shown conflicting results and been limited by small numbers and short follow-up. We aimed to determine if right ventricular septal lead position was associated with a reduction in long-term mortality compared to RVA lead position. Methods: Patients who underwent dual-chamber pacemaker implantation from 2004 through 2013 were evaluated for right ventricular lead position based on chest radiographs. Lead positions were divided in to apical or non-apical. Non-apical lead positions were subdivided to isolate a septal lead position group. Mortality was compared between these groups. Results: During the study period, 3456 patients underwent dual-chamber pacemaker placement and had images appropriate for lead position evaluation. The group was 53.5% male with a mean age of 74 ± 13 years. RVNA lead position was found in 976 (28.2%) patients, including 243 (7.0%) with a septal position. There was no significant difference in age or prior heart failure diagnosis between groups. Kaplan-Meier survival analysis did not reveal a significant difference in mortality between patients with RVA versus RVNA lead position during 5 year follow-up (p = 0.82). However, septal lead position was associated with a significantly lower mortality compared with RVA position (p = 0.03) (figure). Conclusions: Right ventricular septal lead position is associated with a lower long-term mortality than RVA lead position. This has substantial implications regarding the preferred site for ventricular pacing lead placement.